Vonvendi Or Veyvondi Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The vonvendi or veyvondi market research report is one of a series of new reports that provides vonvendi or veyvondi market statistics, including vonvendi or veyvondi industry global market size, regional shares, competitors with a vonvendi or veyvondi market share, detailed vonvendi or veyvondi market segments, market trends and opportunities, and any further data you may need to thrive in the vonvendi or veyvondi industry. This vonvendi or veyvondi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to continued shift toward recombinant therapies, better patient monitoring tools, healthcare system improvements, improvements in blood management programs, and expansion of specialist hematology centers. Major trends in the forecast period include next-generation biologics, emerging biosimilars in development, next-generation monitoring devices, integration of digital health solutions and advancements in treatment protocols.

The growth of the vonvendi or veyvondi market is expected to be fueled by the increasing number of clinical trials. Clinical trials are research studies designed to assess the safety, efficacy, and potential side effects of new treatments, medications, or medical devices. The rise in clinical trials is driven by advancements in medical research, technology, the growing prevalence of chronic and complex diseases, and the aging global population that demands new therapies. Clinical trials help validate the safety and effectiveness of vonvendi or veyvondi, securing regulatory approvals, building trust among healthcare providers and patients, and contributing to the development of optimized treatment protocols that improve accessibility for managing von Willebrand disease. For example, a report published by the Association of the British Pharmaceutical Industry in December 2024 noted that the number of clinical trials initiated rose from 411 in 2022 to 426 in 2023, signaling a gradual recovery. As a result, the growing number of clinical trials is contributing to the expansion of the vonvendi or veyvondi market.

The increasing awareness of bleeding disorders is also expected to drive market growth for vonvendi or veyvondi. These disorders, which affect the blood's ability to clot properly, can lead to excessive bleeding or difficulty stopping bleeding after injury. Raising awareness about these conditions is essential for early diagnosis, better disease management, and improved quality of life for patients. Increased awareness also encourages greater understanding and support within communities and healthcare systems. Vonvendi or veyvondi helps individuals with von Willebrand disease manage their bleeding symptoms by providing a recombinant form of the von Willebrand factor, which enhances platelet adhesion and clot formation, thereby reducing the frequency and severity of bleeding episodes. A report from the World Federation of Hemophilia in October 2022 highlighted that 427,685 individuals were diagnosed with bleeding disorders worldwide, including 100,505 cases of von Willebrand disease. This growing awareness is driving the demand for vonvendi or veyvondi.

Rising healthcare expenditure is also expected to drive the growth of the vonvendi or veyvondi market. Healthcare expenditure refers to the total amount spent on health services and products over a specific period, typically measured annually. The increase in healthcare spending can be attributed to an aging population, the rising prevalence of chronic diseases, advancements in medical technology, higher pharmaceutical costs, and the expansion of healthcare access and services. This increased spending supports the adoption of treatments such as vonvendi or veyvondi by enabling greater investment in advanced therapies for von Willebrand disease, expanding patient access, and enhancing research and development efforts. Additionally, it improves healthcare infrastructure to meet complex medical needs. For instance, the Office for National Statistics reported in May 2024 that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared to a 0.9% growth in 2022. This rise in healthcare expenditure is contributing to the growth of the vonvendi or veyvondi market.

The key company operating in the vonvendi or veyvondi market is Takeda Pharmaceutical Co. Ltd.

North America was the largest region in the vonvendi or veyvondi market in 2024. The regions covered in vonvendi or veyvondi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vonvendi or veyvondi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Vonvendi, also known as Veyvondi, is a brand name for recombinant von Willebrand factor (rVWF), a medication used to treat and manage bleeding episodes in patients with von Willebrand disease (VWD). It works by replacing the deficient or dysfunctional von Willebrand factor, which helps control bleeding in these patients.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main clinical indications for vonvendi include von Willebrand disease types 1, 2, and 3. Type 1 VWD, the most common form, affects 60% to 80% of individuals with the condition. Vonvendi is distributed through various channels, including hospitals, retail pharmacies, online pharmacies, and specialty pharmacies. It serves a broad range of end-users, including adults, pediatric patients, and geriatric populations.

The vonvendi or veyvondi market consists of sales of on-demand treatment and perioperative management. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.